• Nasodine Nasal Spray approved for importation and distribution in Indonesia
• Indonesia is the largest market in Southeast Asia with a population of 285 million
• This is the first regulatory approval for Nasodine

Firebrick Pharma Ltd (ASX:FRE) has announced that its Nasodine Nasal Spray ('Nasodine') has been approved by the Indonesian Government as an 'antiseptic' product within the 'Household Health Supplies' category. The approval allows for the importation and marketing of Nasodine Nasal Spray in Indonesia, effective immediately. The approval follows the submission of a technical dossier to the Ministry of Health ('MoH') in Indonesia last year, conducted on Firebrick's behalf by an Indonesian company, PT Pyridam Farma Tbk ('Pyridam') and its affiliate import agent, PT Mursmedic, acting as regulatory agents for Firebrick. Under the Product Registration Services Agreement with Pyridam, Firebrick can now utilize the Nasodine approval and commence importation and distribution of the product in Indonesia. With a population of around 285 million, Indonesia is the largest market in Southeast Asia and the 4th most populous country in the world. This approval is a pivotal event for Firebrick and a significant value inflection point for the company. Before importation, distribution and sales of Nasodine can commence, Firebrick will need to manufacture the product in local language packaging and secure a local marketing partner, which will be a priority project for the company's new Head of Business Development and Licensing.

Firebrick is pursuing approval for Nasodine in other markets, including the Philippines, and plans to expand sales to up to 10 markets over the next three years.